The abstract is read at the publisher; the summary is JClub's.
Host germline genomics can improve infectious disease management by enabling earlier detection of inborn errors of immunity and supporting risk stratification and therapy selection.
- Why it matters: Current clinical genomic use focuses mainly on pathogens, leaving patients’ inherited immune variants underused for guiding care, especially for rare inborn errors of immunity.
- What they did: A multidisciplinary group of over 30 clinical immunologists, infectious disease specialists, and geneticists outlined implementation challenges and opportunities for using host genomics in infectious disease management.
- The result: Key barriers include payer requirements, limited EHR interoperability, and insufficient evidence on efficacy and cost-effectiveness; proposed priorities are better IEI indicators, EHR integration, and multidisciplinary identification.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.